Invisible manThe elephant in the room problem we have atm is that we have a big pharma CEO that thinks that increasing sales will increase stock valuation. That's the way in big pharma, that's what he understands and our Chairwomen understand. It's their background and belief. Ok the problem is that biotechs are not about sales but about pipeline. That is why you have many biotects with promissing stuff worht tenfold what our mini pharma is worth atm. Where is that CEO.. we don't hear him, we don't see him, where... promoting is not as sin and Thera needs a better promoter. Wrong person at the wrong time 101.